NEW YORK ( TheStreet) -- BioMarin Pharmaceuticals Inc (Nasdaq: BMRN) hit a new 52-week high Friday as it is currently trading at $34.74, above its previous 52-week high of $34.50 with 208,275 shares traded as of 10:01 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

BioMarin has a market cap of $3.6 billion and is part of the health care sector and drugs industry. Shares are up 23.5% year to date as of the close of trading on Thursday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions. The company has a P/E ratio of 16.9, below the average drugs industry P/E ratio of 20.4 and below the S&P 500 P/E ratio of 17.7.
  • Practice your BMRN trading strategies and win cash in our stock game.

TheStreet Ratings rates BioMarin as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and feeble growth in the company's earnings per share. You can view the full BioMarin Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.